- Home
- COLL vs BHVN Comparison
COLL vs BHVN Comparison
Compare COLL & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- BHVN
- Stock Information
- Founded
- COLL 2002
- BHVN 2013
- Country
- COLL United States
- BHVN United States
- Employees
- COLL N/A
- BHVN N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- COLL Health Care
- BHVN Health Care
- Exchange
- COLL Nasdaq
- BHVN Nasdaq
- Market Cap
- COLL 1.1B
- BHVN 1.1B
- IPO Year
- COLL 2015
- BHVN 2017
- Fundamental
- Price
- COLL $45.49
- BHVN $8.15
- Analyst Decision
- COLL Strong Buy
- BHVN Strong Buy
- Analyst Count
- COLL 5
- BHVN 16
- Target Price
- COLL $45.40
- BHVN $37.07
- AVG Volume (30 Days)
- COLL 520.4K
- BHVN 5.6M
- Earning Date
- COLL 11-06-2025
- BHVN 11-10-2025
- Dividend Yield
- COLL N/A
- BHVN N/A
- EPS Growth
- COLL N/A
- BHVN N/A
- EPS
- COLL 1.63
- BHVN N/A
- Revenue
- COLL $757,067,000.00
- BHVN N/A
- Revenue This Year
- COLL $21.41
- BHVN N/A
- Revenue Next Year
- COLL $3.28
- BHVN $2,079.03
- P/E Ratio
- COLL $28.29
- BHVN N/A
- Revenue Growth
- COLL 26.34
- BHVN N/A
- 52 Week Low
- COLL $23.23
- BHVN $7.48
- 52 Week High
- COLL $48.18
- BHVN $47.75
- Technical
- Relative Strength Index (RSI)
- COLL 74.50
- BHVN 29.25
- Support Level
- COLL $35.26
- BHVN $7.48
- Resistance Level
- COLL $48.18
- BHVN $8.77
- Average True Range (ATR)
- COLL 1.74
- BHVN 1.12
- MACD
- COLL 0.93
- BHVN -0.57
- Stochastic Oscillator
- COLL 80.20
- BHVN 6.59
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.